The PBM Crisis Explained

The 30-second version

Six pharmacy benefit managers — CVS Caremark, Express Scripts, OptumRx, Humana, Prime Therapeutics, and MedImpact — control roughly 95% of U.S. prescriptions. They sit between you, the patient, and the insurance plan. They decide what you get paid, when you get paid, and how much they take back later. They also own competing pharmacies, mail-order operations, and specialty networks. The conflict of interest is the business model.

The result: independent pharmacies have been closing at the rate of about one per day. Forty-five percent of U.S. counties are now classified as pharmacy deserts. The pressure is not coming from your patients, your staff, or your stock. It’s coming from the middle layer that nobody asked for.

What a PBM actually is, in 90 seconds

A PBM was originally supposed to be a claims processor. Insurance plans hired them to handle the technical work of paying pharmacies. Over forty years, they consolidated, vertically integrated with insurers and pharmacies, and quietly took control of the entire prescription supply chain.

Today a PBM does six things that affect you directly: it builds the formulary (which drugs are covered), sets the reimbursement rate (what you get paid per fill), runs the prior authorization process (the black hole), administers DIR fees and clawbacks (money taken back after you’ve already filled), operates spread pricing (charging the plan more than they pay you and pocketing the difference), and steers patients toward their own pharmacies.

Every one of those levers can be pulled against you, and most of them get pulled at once.

How they got to 95%

Three waves of consolidation got us here. In the early 2000s, the big three PBMs absorbed most of the smaller players. In the 2010s, they merged with insurers — CVS bought Aetna, Cigna bought Express Scripts, UnitedHealth’s OptumRx wraps the same parent that owns the country’s largest insurance carrier. By 2020, the remaining independents were either acquired or starved of network access.

What the FTC published in its 2024 interim report was not a surprise to anyone behind a counter. It just put numbers on what every pharmacist had felt for a decade: the people negotiating your reimbursement own a competing pharmacy, run a competing mail-order operation, and direct patients away from your store. The same companies write the rules and play the game.

The mechanics of getting paid less

Here are the levers, in plain language.

Reimbursement rates. The PBM tells you what you’ll be paid per fill. Sometimes it’s below the wholesale cost of the drug. There is a public example, often quoted by Benjamin Jolley: a 90-day Lamotrigine fill that paid 35 cents total, with a 30-cent transmission fee, leaving the pharmacy 5 cents in revenue for the entire prescription. That is not an outlier; it is the floor.

MAC pricing. The maximum allowable cost is what the PBM says they’ll pay for a generic, and you have almost no real way to dispute it. Prices update without warning. You can fill a script today at a healthy margin and the same script next week at a loss.

DIR fees and clawbacks. After you’ve filled the prescription and been paid, the PBM can come back months later and demand a portion back — sometimes 5 to 12 percent of the original payment — based on quality metrics that often have nothing to do with the actual fill. The 2024 CMS rule shifted some of this to point-of-sale, but the underlying mechanism still exists in commercial plans.

Spread pricing. The plan pays the PBM $40 for a script. The PBM pays you $12. The PBM keeps $28. You see only your $12. The plan only sees the $40. Neither party can independently audit the spread without forensic work.

Prior authorization. Not directly a payment lever, but a time tax. Hours of your tech’s week disappear into PA portals that exist mostly to slow approvals.

Patient steering. The PBM’s preferred network always seems to include their own retail or mail-order pharmacy. Your patient gets a letter telling them to switch.

Why your reimbursement keeps shrinking

Three things are compounding at once. PBMs have more market power than they did a decade ago. Manufacturers are paying larger rebates that flow upstream and never reach you or the patient. And the same companies are taking equity positions in mail-order, specialty, and retail — so every script that lands in your store instead of theirs is, from their accounting, a loss.

If it feels like the system is structurally tilted against the independent corner pharmacy, that’s because it is.

What’s actually changing in 2026

The FTC interim report is out and a follow-up is expected. Multiple state legislatures have passed PBM reform bills with real teeth — banning spread pricing for state plans, requiring NADAC-based reimbursement, mandating dispensing fee floors. The federal bills (PBM Transparency Act and successors) keep almost passing. Class actions on DIR fees are working their way through.

Mark Cuban Cost Plus Drug Company has shown the country what transparent pharmacy pricing looks like. Patients now know the words “cost-plus” and “markup,” and they’re asking why their insurance is paying more than the cash price.

The political wind is at your back for the first time in twenty years. The financial squeeze is still on. Both things are true.

What you can actually do about it

I can’t change the PBM industry from a blog post. Neither can you. But here are five things that are inside your control and meaningfully change the math.

1. Audit your software stack quarterly. Most independents are paying $4–12k/mo for tools they barely use. The single fastest way to recover margin is to cancel things you forgot you were paying for. Our pilot pharmacy cut $1,800/mo from week-one waste alone. That is real money back in your pocket without negotiating a single PBM contract.

2. Move retention upstream of acquisition. PBMs steer patients away. The countermove is to make leaving harder before the letter arrives. Refill texts that work, MTM follow-ups that get booked, vaccine campaigns timed to the season, transfer-in offers that name the friction point at the chain. Pharmacy-native marketing — not generic agency stuff — recovers patients faster than the PBM steers them.

3. Run the math on every contract you sign. Not just the headline reimbursement; the DIR exposure, the MAC update cadence, the PA volume baked into your network. If the math doesn’t work, decline the network. Some independents have meaningfully recovered margin by walking away from one or two PBMs they couldn’t make profitable.

4. Diversify revenue past the prescription counter. Vaccinations, MTMs, clinical services, point-of-care testing, durable medical equipment, compounding (if you’re set up for it). Cash and clinical revenue are not subject to PBM clawbacks. Every dollar of non-Rx revenue is a dollar the middle layer cannot touch.

5. Get loud, locally. State pharmacy boards, NCPA, your state’s pharmacy advocacy group, and your federal representatives. The reform that’s passing right now is passing because pharmacists wrote letters and showed up. Your hour matters more in the next twelve months than in the previous ten years.

The honest take

Software won’t save you alone. Marketing won’t save you alone. Even good math and good advocacy won’t save you alone. What works is the stack: a tighter operating layer (fewer tools, better workflows), a sharper retention engine (patients stay longer), a cleaner contract book (decline what doesn’t pay), more non-Rx revenue, and pressure on the people writing the rules.

That’s the boring answer. It’s also the only one that matches what we’ve seen actually move numbers in real pharmacies. If any of that sounds like the work you should already be doing, that’s the whole point of the audit call we offer. Free. Thirty minutes. Specific dollars on the table by the end of it.

— Aaron